Lumicitabine
- Generic Name
- Lumicitabine
- Drug Type
- Small Molecule
- Chemical Formula
- C18H25ClFN3O6
- CAS Number
- 1445385-02-3
- Unique Ingredient Identifier
- BNW5PQ52G1
- Background
Lumicitabine is under investigation in clinical trial NCT03010059 (A Study to Assess the Relative Bioavailability of JNJ64041575 Administered as 2 Different New Concept Formulations (Oral Suspension and Tablet) Compared to Their Respective Current Formulations, and to Assess the Effect of Food on the Pharmacokinetics of the 2 New Concept Formulations).
A Study of ALS-008176 in Infants Hospitalized With RSV
Phase 1
Completed
- Conditions
- Respiratory Syncytial Virus Infections
- Interventions
- Drug: Placebo
- First Posted Date
- 2014-07-29
- Last Posted Date
- 2025-02-03
- Lead Sponsor
- Alios Biopharma Inc.
- Target Recruit Count
- 183
- Registration Number
- NCT02202356
- Locations
- 🇺🇸
The Research Institute at Nationwide Children's Hospital, Columbus, Ohio, United States
🇦🇺The Canberra Hospital, Canberra, Australia
🇦🇺Princess Margaret Hospital, Perth, Australia
A Phase 2a Study to Evaluate ALS-008176 in the Virus Challenge Model
Phase 2
Completed
- Conditions
- Respiratory Syncytial Virus Infections
- Interventions
- Drug: vehicle
- First Posted Date
- 2014-03-21
- Last Posted Date
- 2025-02-03
- Lead Sponsor
- Alios Biopharma Inc.
- Target Recruit Count
- 62
- Registration Number
- NCT02094365
- Locations
- 🇬🇧
Retroscreen Virology Ltd, London, United Kingdom
Study of Single and Multiple Doses of ALS-008176 in Healthy Volunteers
Phase 1
Completed
- Conditions
- Respiratory Syncytial Virus Infections
- Interventions
- Drug: Placebo
- First Posted Date
- 2013-07-24
- Last Posted Date
- 2017-10-31
- Lead Sponsor
- Alios Biopharma Inc.
- Target Recruit Count
- 101
- Registration Number
- NCT01906164
- Locations
- 🇫🇷
Investigational Site, Rennes, France
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.
© Copyright 2025. All Rights Reserved by MedPath